Overview

• U.S. neuro devices firm's Q1 revenue rose 43% yr/yr, beating analyst expectations

• Gross margin expanded to 64% from 60% yr/yr

• Operating expenses rose 44% due to IRRAflow integration and higher personnel costs

Outlook

• ClearPoint Neuro estimates 2026 revenue between $52.0 mln and $56.0 mln

• Company expects cost synergies from IRRAflow integration to reduce cash burn in H2 2026

• ClearPoint Neuro anticipates IRRAflow integration could be cash neutral for full year 2027

Result Drivers

• IRRAFLOW INTEGRATION - Revenue growth was driven by the integration of IRRAflow products and team, contributing to higher neurosurgery navigation and access revenue

• DEVICE AND NAVIGATION GROWTH - Neurosurgery navigation, therapy and access revenue rose 80% yr/yr, supported by additional IRRAflow sales and the introduction of 3.0 operating room navigation software

• CAPITAL EQUIPMENT SALES - Capital equipment and software revenue increased 177% yr/yr due to more placements of navigation capital, IRRAflow control units, and Prism laser units

Company press release: ID:nACS9Lz32a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Beat	$12.10 mln	$11.97 mln (3 Analysts)
Q1 Gross Margin		64.00%
Q1 Operating Expenses		$16.20 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Clearpoint Neuro Inc is $20.00, about 58.2% above its May 12 closing price of $12.64

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.